These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 18986296)

  • 1. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
    Tillotson GS; Echols RM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM; Tillotson GS; Song JX; Tosiello RL
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of recent studies of community-acquired pneumonia.
    Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and microbiological end points in the treatment of pneumonia.
    Musher DM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S207-9. PubMed ID: 18986291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
    Bartlett JG
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it possible to blind a trial for community-acquired pneumonia?
    Boucher HW
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.
    Ambrose PG
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S225-31. PubMed ID: 18986294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
    Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?
    Talbot GH
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S180-5. PubMed ID: 18986286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical end points of therapy for patients with mild community-acquired pneumonia.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
    Bradley JS; McCracken GH
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
    Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
    J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia.
    Metlay JP
    Infect Dis Clin North Am; 2004 Dec; 18(4):777-90. PubMed ID: 15555824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How long should we treat community-acquired pneumonia?
    Scalera NM; File TM
    Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
    Laessig KA
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for treatment of community-acquired pneumonia.
    Kim MK; Nightingale C; Quintiliani R
    Conn Med; 2001 Aug; 65(8):473-5. PubMed ID: 11550446
    [No Abstract]   [Full Text] [Related]  

  • 20. Community acquired pneumonia.
    Loeb M
    Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.